Although it “has stirred significant controversy in recent years,” the Congressional Research Service policy of restricting direct dissemination of its products to members of Congress is well-founded, argued CRS director Daniel P. Mulhollan in a lengthy internal memorandum (pdf) last month.
“The reasons for limiting public distribution of our work can be summarized as follows,” he wrote.
“First, there is a danger that placing CRS in an intermediate position [between Congress and the public] would threaten the dialog on policy issues between Members and their constituents.”
“Second, the current judicial … perception of CRS as ‘adjunct staff’ of the Congress might be altered if CRS were seen as speaking directly to the public, putting at risk Speech or Debate Clause constitutional protections afforded the confidential work performed by this agency.”
“And third, if CRS products were routinely disseminated broadly to the public, over time these products might come to be written with a large public audience in mind and would no longer be focused solely on congressional needs.”
A copy of Director Mulhollan’s seven page memorandum on “Access to CRS Reports,” dated April 18, 2007, was obtained by Secrecy News and is available here.
The arguments detailed by Mr. Mulhollan seem singularly unpersuasive to an outsider. CRS is not being called upon to mediate between Congress and the public or to engage in a public dialog on policy issues. Rather, proponents of broader dissemination are simply asking for the same public access that commercial vendors of CRS reports already enjoy.
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.
Called today to speak on behalf of U.S. science and technology, Dr. Jedidah Isler, astrophysicist, educator, strategist, policy-maker, and science communicator, will provide constructive, nonpartisan feedback to the House Committee’s hearing “American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership.”
“Federal data and access to it is not a partisan issue. It is a people issue. Our country cannot achieve greatness without access to the data that measure what we value, who we are, and where we’re heading.”
The United States’ biosecurity governance system is structurally incapable of detecting and responding to certain classes of threats. U.S. biosecurity tools have not kept pace with technological advancements or a changing threat landscape.